Abstract
Up to now, survivin has been recommended as a prognostic and diagnostic indicator in glioma patients. However, there are still many controversies. Here, a meta-analysis was conducted to draw a more definitive conclusion on the correlation of survivin with overall survival (OS), age, gender, and WHO grade. Eligible studies were available through careful assessment, and then pooled hazard ratios (HRs) or odds ratios (ORs) with 95 % confidence intervals (95 % CIs) were estimated. Funnel plots were introduced to evaluate the publication bias. Additionally, heterogeneity and sensitivity were also evaluated. In the present meta-analysis, 15 eligible studies with a total of 1,089 patients were incorporated. Survivin expression in gliomas correlated with 2-year OS (n = 8; HR 0.17, 95 % CI 0.11–0.26) and 5-year OS (n = 7; HR 0.12, 95 % CI 0.07–0.22) in patients. In addition, a fixed-effect model revealed a significant association between survivin and age (male/+; OR 2.10, 95 % CI 1.44–3.05) and survivin and WHO grade (I+II/+; OR 0.27, 95 % CI 0.19–0.38). No heterogeneity was observed across all studies. According to Begg’s and Egger’s test and funnel plot, no publication bias was reported. Taken together, our meta-analysis suggests that survivin expression is associated with poor survival, older age, and higher WHO grade and could be suggested as a useful prognostic and diagnostic biomarker, or an effective therapy target.
Similar content being viewed by others
References
Louis DN, Pomeroy SL, Cairncross JG (2002) Focus on central nervous system neoplasia. Cancer Cell 1(2):125–128
Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917–921
Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE (2004) Nuclear survivin as a biomarker for non-small-cell lung cancer. Brit J Cancer 91(3):537–540
Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M (2003) Prognostic importance of survivin in breast cancer. Brit J Cancer 88(7):1077–1083
Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, Torzilli G, Santambrogio R, Spinelli A, Coggi G, Bosari S (2006) Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology 54(79):2040–2044
Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN, Fu LA, He XS, Ma FC (2005) Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104(12):2775–2783
Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K (2003) Expression of survivin in astrocytic tumors. Cancer 97(4):1077–1083
Tamm I, Wang Y, Sausville ED, Scudiero DA, Vigna N, Oltersdorf T, Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58(23):5315–5320
Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rössler K, Budka H, Hainfellner JA (2005) No prognostic impact of survivin expression in glioblastoma. Acta Neuropathol 109(5):534–538
Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Suzuki Y, Itoh H, Ishiuchi S, Sakurai H, Hasegawa M, Nakano T (2009) Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neuro Oncol 91(3):353–358
Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T, Arita K, Kurisu K (2007) Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neuro Oncol 82(2):193–198
Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ, Sculier JP (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18(4):705–719
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8(1):16
Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ, Loeffler JS (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20(4):1063–1068
Song XB, Yuan XH, Jiang PC, Cao CJ (2003) The prognosis and clinicopathology of survivin in glioma patients. Cent Chin Med J 27(6):232–324
Jiao BH, Yao ZG, Qiu SM, Bai BZ (2004) Apoptosis in brain gliomas and expression of apoptosis related genes Fas and survivin. Chin J Neurosurg Dis Res 3(1):20–24
Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JST, Guan XY (2006) Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Brit J Cancer 94(1):108–114
Pan Y, Hu WH, Xie D, Wu HX, Xiang J, Liu YD, Wu QL, Liu YH (2006) Nuclear expression of survivin in glioma and its correlation to prognosis. Chin J Canc 25(5):635–639
Shou JX, Lin AQ, Wang XJ, Wu JX, Shan Q, Li PD, Liu Q (2006) Expression of survivin in human glioma tissue. Acta Acad Med Z 41(3):566–567
Pan Y, Hu WH, Xie D, Wu QL, Liu YH, Xiang J, Wu XH (2007) Nuclear and cytoplasmic expressions of survivin in glioma and their prognostic value. Chin Med J 87(5):325–329
Liu YF, Shi GS, Zhang S, Zhang JG, Huang H (2008) Correlation of the expression of p33/ING1 and survivin proteins with prognosis in human astrocytoma. J Mod Oncol 16(9):1490–1492
Zhang Z, Su N, Wang Z (2009) Detection of survivin and Bcl-2 in gliomas via tissue microassay. J Inn Mon Univ Nat 15(5):18–20
Kogiku M, Ohsawa I, Matsumoto K, Sugisaki Y, Takahashi H, Teramoto A, Ohta S (2008) Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci 15(11):1198–1203
Zhen H, Zhang X, Yang T, Hu P, Fu L, Ma F, Wang X, Liang J (2005) Expression of survivin and its significance in human brain glioma. Chin J Clin Oncol 32(1):6–12
Guo D, Xin R, Liu L, Yu D, Wang Z (2004) Survivin protein expression in gliomas and its correlation with malignancy of gliomas. Acta Acad Milita Tert 26(2):162–164
Guan HT, Xue XH, Wang XJ, Li A, Qin ZY (2006) Knockdown of survivin expression by small interfering RNA suppresses proliferation of two human cancer cell lines. Chin Med Sci J 21(2):115–119
Begg CB, Berlin JA (1988) Publication bias: a problem in interpreting medical data. J R Stat Soc A 81(2):107–115
Acknowledgments
This study was supported by Shandong University Science Technology Innovation Foundation (201410422123). We greatly thank Ruiyang Yi in Sandy lab for valuable suggestions and writing.
Disclosure
The authors state that there are no conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Additional information
Shunzeng Lv and Congxin Dai contributed equally to this work.
An erratum to this article is available at http://dx.doi.org/10.1007/s12035-017-0402-0.
This article has been retracted at the request of the Editor-in-Chief and the Publisher. The article shows evidence of irregularities in authorship during the submission process. There is strong reason to believe that the peer review process was compromised and the authors have plagiarized parts from the following article:
Shunzeng Lv, Ekaterina Turlova, Shigang Zhao, Huihui Kang, Mingzhi Han, Hong-Shuo Sun, Prognostics and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis. Tumor Biol. (2014) 35: 1565. doi:10.1007/s13277-013-1216-y Received: 23 July 2013
In addition, the article shows similarities with the following article which was submitted within a close timeframe:
Xiangshan Yang, Shunzeng Lv, Yuting Liu, Daotang Li, Ranran Shi, Zhenyu Tang, Jianzhen Fan, Zhongfa Xu, The Clinical Utility of Matrix Metalloproteinase 9 in Evaluating Pathological Grade and Prognosis of Glioma Patients: A Meta-Analysis. Mol Neurobiol (2015) 52: 38. doi:10.1007/s12035-014-8850-2 Received: 20 July 2014
The article “The impact of survivin on prognosis and clinicopathology of glioma patients: a systematic meta-analysis” was received on 26 June 2014.
As such the validity of the content of this article cannot be verified.
About this article
Cite this article
Lv, S., Dai, C., Liu, Y. et al. RETRACTED ARTICLE: The Impact of Survivin on Prognosis and Clinicopathology of Glioma Patients: A Systematic Meta-Analysis. Mol Neurobiol 51, 1462–1467 (2015). https://doi.org/10.1007/s12035-014-8823-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-014-8823-5